BlackRock, Inc. 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged |
2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
BLACKROCK INC BLK |
3,755,504 9.900% |
0 (Unchanged) |
Filing |
| 2024-10-21 4:11 pm Purchase |
2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
BLACKROCK INC BLK |
3,755,504 9.900% |
1,240,380 (+49.32%) |
Filing |
| 2024-01-26 11:49 am Purchase |
2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
BLACKROCK INC BLK |
2,515,124 7.600% |
1,188,593 (+89.60%) |
Filing |
| 2023-02-09 11:01 am Sale |
2023-01-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
BLACKROCK INC BLK |
1,326,531 4.900% |
-14,728 (-1.10%) |
Filing |
| 2023-02-08 1:16 pm Purchase |
2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
BLACKROCK INC BLK |
1,341,259 5.000% |
1,341,259 (New Position) |
Filing |